Fuyuhiko Tamanoi - Publications

Affiliations: 
Microbiology, Immunology, & Molecular Genetics 0440 University of California, Los Angeles, Los Angeles, CA 
Area:
Nanotechnology, Cell Biology

64 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2015 Lu J, Yoshimura K, Goto K, Lee C, Hamura K, Kwon O, Tamanoi F. Nanoformulation of Geranylgeranyltransferase-I Inhibitors for Cancer Therapy: Liposomal Encapsulation and pH-Dependent Delivery to Cancer Cells. Plos One. 10: e0137595. PMID 26352258 DOI: 10.1371/journal.pone.0137595  0.76
2015 Chantaravisoot N, Wongkongkathep P, Loo JA, Mischel PS, Tamanoi F. Significance of filamin A in mTORC2 function in glioblastoma. Molecular Cancer. 14: 127. PMID 26134617 DOI: 10.1186/s12943-015-0396-z  0.6
2015 Finlay J, Roberts CM, Dong J, Zink JI, Tamanoi F, Glackin CA. Mesoporous silica nanoparticle delivery of chemically modified siRNA against TWIST1 leads to reduced tumor burden. Nanomedicine : Nanotechnology, Biology, and Medicine. PMID 26115637 DOI: 10.1016/j.nano.2015.05.011  0.76
2015 Mortazavi F, Lu J, Phan R, Lewis M, Trinidad K, Aljilani A, Pezeshkpour G, Tamanoi F. Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis. Bmc Cancer. 15: 381. PMID 25956913 DOI: 10.1186/s12885-015-1360-4  0.76
2015 Sato T, Akasu H, Shimono W, Matsu C, Fujiwara Y, Shibagaki Y, Heard JJ, Tamanoi F, Hattori S. Rheb protein binds CAD (carbamoyl-phosphate synthetase 2, aspartate transcarbamoylase, and dihydroorotase) protein in a GTP- and effector domain-dependent manner and influences its cellular localization and carbamoyl-phosphate synthetase (CPSase) activity. The Journal of Biological Chemistry. 290: 1096-105. PMID 25422319 DOI: 10.1074/jbc.M114.592402  0.76
2015 Hwang AA, Lu J, Tamanoi F, Zink JI. Functional nanovalves on protein-coated nanoparticles for in vitro and in vivo controlled drug delivery. Small (Weinheim An Der Bergstrasse, Germany). 11: 319-28. PMID 25196485 DOI: 10.1002/smll.201400765  0.76
2014 Théron C, Gallud A, Carcel C, Gary-Bobo M, Maynadier M, Garcia M, Lu J, Tamanoi F, Zink JI, Wong Chi Man M. Hybrid mesoporous silica nanoparticles with pH-operated and complementary H-bonding caps as an autonomous drug-delivery system. Chemistry (Weinheim An Der Bergstrasse, Germany). 20: 9372-80. PMID 24986399 DOI: 10.1002/chem.201402864  0.76
2014 Heard JJ, Fong V, Bathaie SZ, Tamanoi F. Recent progress in the study of the Rheb family GTPases Cellular Signalling. 26: 1950-1957. PMID 24863881 DOI: 10.1016/j.cellsig.2014.05.011  0.76
2014 Croissant J, Chaix A, Mongin O, Wang M, Clément S, Raehm L, Durand JO, Hugues V, Blanchard-Desce M, Maynadier M, Gallud A, Gary-Bobo M, Garcia M, Lu J, Tamanoi F, et al. Two-photon-triggered drug delivery via fluorescent nanovalves. Small (Weinheim An Der Bergstrasse, Germany). 10: 1752-5. PMID 24678053 DOI: 10.1002/smll.201400042  0.76
2014 Coffman K, Yang B, Lu J, Tetlow AL, Pelliccio E, Lu S, Guo DC, Tang C, Dong MQ, Tamanoi F. Characterization of the Raptor/4E-BP1 interaction by chemical cross-linking coupled with mass spectrometry analysis. The Journal of Biological Chemistry. 289: 4723-34. PMID 24403073 DOI: 10.1074/jbc.M113.482067  0.76
2013 Croissant J, Maynadier M, Gallud A, Peindy N'dongo H, Nyalosaso JL, Derrien G, Charnay C, Durand JO, Raehm L, Serein-Spirau F, Cheminet N, Jarrosson T, Mongin O, Blanchard-Desce M, Gary-Bobo M, ... ... Tamanoi F, et al. Two-photon-triggered drug delivery in cancer cells using nanoimpellers. Angewandte Chemie (International Ed. in English). 52: 13813-7. PMID 24214916 DOI: 10.1002/anie.201308647  0.76
2013 Zimonjic DB, Chan LN, Tripathi V, Lu J, Kwon O, Popescu NC, Lowy DR, Tamanoi F. In vitro and in vivo effects of geranylgeranyltransferase I inhibitor P61A6 on non-small cell lung cancer cells. Bmc Cancer. 13: 198. PMID 23607551 DOI: 10.1186/1471-2407-13-198  0.76
2013 Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, Villa GR, Tanaka K, Nael A, Yang H, Dang J, Vinters HV, Yong WH, Flagg M, Tamanoi F, et al. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discovery. 3: 534-47. PMID 23533263 DOI: 10.1158/2159-8290.CD-12-0502  0.76
2013 Yanes RE, Tarn D, Hwang AA, Ferris DP, Sherman SP, Thomas CR, Lu J, Pyle AD, Zink JI, Tamanoi F. Involvement of lysosomal exocytosis in the excretion of mesoporous silica nanoparticles and enhancement of the drug delivery effect by exocytosis inhibition. Small (Weinheim An Der Bergstrasse, Germany). 9: 697-704. PMID 23152124 DOI: 10.1002/smll.201201811  0.76
2012 Nakashima A, Otsubo Y, Yamashita A, Sato T, Yamamoto M, Tamanoi F. Psk1, an AGC kinase family member in fission yeast, is directly phosphorylated and controlled by TORC1 and functions as S6 kinase Journal of Cell Science. 125: 5840-5849. PMID 22976295 DOI: 10.1242/jcs.111146  0.76
2012 Rettig M, Trinidad K, Pezeshkpour G, Frost P, Sharma S, Moatamed F, Tamanoi F, Mortazavi F. PAK1 kinase promotes cell motility and invasiveness through CRK-II serine phosphorylation in non-small cell lung cancer cells. Plos One. 7: e42012. PMID 22848689 DOI: 10.1371/journal.pone.0042012  0.76
2012 Hon NK, Shaposhnik Z, Diebold ED, Tamanoi F, Jalali B. Tailoring the biodegradability of porous silicon nanoparticles. Journal of Biomedical Materials Research. Part A. 100: 3416-21. PMID 22767395 DOI: 10.1002/jbm.a.34294  0.76
2012 Lau YA, Henderson BL, Lu J, Ferris DP, Tamanoi F, Zink JI. Continuous spectroscopic measurements of photo-stimulated release of molecules by nanomachines in a single living cell. Nanoscale. 4: 3482-9. PMID 22552632 DOI: 10.1039/c2nr30524k  0.76
2012 Yanes RE, Tamanoi F. Development of mesoporous silica nanomaterials as a vehicle for anticancer drug delivery. Therapeutic Delivery. 3: 389-404. PMID 22506096 DOI: 10.4155/tde.12.9  0.76
2012 Lu J, Li Z, Zink JI, Tamanoi F. In vivo tumor suppression efficacy of mesoporous silica nanoparticles-based drug-delivery system: enhanced efficacy by folate modification. Nanomedicine : Nanotechnology, Biology, and Medicine. 8: 212-20. PMID 21703996 DOI: 10.1016/j.nano.2011.06.002  0.76
2011 Chan LN, Fiji HD, Watanabe M, Kwon O, Tamanoi F. Identification and characterization of mechanism of action of P61-E7, a novel phosphine catalysis-based inhibitor of geranylgeranyltransferase-I. Plos One. 6: e26135. PMID 22028818 DOI: 10.1371/journal.pone.0026135  0.76
2011 Xue M, Zhong X, Shaposhnik Z, Qu Y, Tamanoi F, Duan X, Zink JI. pH-Operated mechanized porous silicon nanoparticles. Journal of the American Chemical Society. 133: 8798-801. PMID 21595466 DOI: 10.1021/ja201252e  0.76
2011 Ferris DP, Lu J, Gothard C, Yanes R, Thomas CR, Olsen JC, Stoddart JF, Tamanoi F, Zink JI. Synthesis of biomolecule-modified mesoporous silica nanoparticles for targeted hydrophobic drug delivery to cancer cells. Small (Weinheim An Der Bergstrasse, Germany). 7: 1816-26. PMID 21595023 DOI: 10.1002/smll.201002300  0.76
2011 Hardt M, Chantaravisoot N, Tamanoi F. Activating mutations of TOR (target of rapamycin). Genes to Cells : Devoted to Molecular & Cellular Mechanisms. 16: 141-51. PMID 21210909 DOI: 10.1111/j.1365-2443.2010.01482.x  0.76
2010 Meng H, Xue M, Xia T, Zhao YL, Tamanoi F, Stoddart JF, Zink JI, Nel AE. Autonomous in vitro anticancer drug release from mesoporous silica nanoparticles by pH-sensitive nanovalves. Journal of the American Chemical Society. 132: 12690-7. PMID 20718462 DOI: 10.1021/ja104501a  0.76
2010 Lu J, Liong M, Li Z, Zink JI, Tamanoi F. Biocompatibility, biodistribution, and drug-delivery efficiency of mesoporous silica nanoparticles for cancer therapy in animals. Small (Weinheim An Der Bergstrasse, Germany). 6: 1794-805. PMID 20623530 DOI: 10.1002/smll.201000538  0.76
2010 Jiang H, Song C, Chen CC, Xu R, Raines KS, Fahimian BP, Lu CH, Lee TK, Nakashima A, Urano J, Ishikawa T, Tamanoi F, Miao J. Quantitative 3D imaging of whole, unstained cells by using X-ray diffraction microscopy. Proceedings of the National Academy of Sciences of the United States of America. 107: 11234-9. PMID 20534442 DOI: 10.1073/pnas.1000156107  0.76
2010 Hom C, Lu J, Liong M, Luo H, Li Z, Zink JI, Tamanoi F. Mesoporous silica nanoparticles facilitate delivery of siRNA to shutdown signaling pathways in mammalian cells. Small (Weinheim An Der Bergstrasse, Germany). 6: 1185-90. PMID 20461725 DOI: 10.1002/smll.200901966  0.76
2009 Klichko Y, Liong M, Choi E, Angelos S, Nel AE, Stoddart JF, Tamanoi F, Zink JI. Mesostructured Silica for Optical Functionality, Nanomachines, and Drug Delivery. Journal of the American Ceramic Society. American Ceramic Society. 92: s2-s10. PMID 19834571 DOI: 10.1111/j.1551-2916.2008.02722.x  0.76
2009 Chan LN, Hart C, Guo L, Nyberg T, Davies BS, Fong LG, Young SG, Agnew BJ, Tamanoi F. A novel approach to tag and identify geranylgeranylated proteins. Electrophoresis. 30: 3598-606. PMID 19784953 DOI: 10.1002/elps.200900259  0.76
2009 Lu J, Chan L, Fiji HD, Dahl R, Kwon O, Tamanoi F. In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I. Molecular Cancer Therapeutics. 8: 1218-26. PMID 19417142 DOI: 10.1158/1535-7163.MCT-08-1122  0.76
2009 Sato T, Nakashima A, Guo L, Tamanoi F. Specific activation of mTORC1 by Rheb G-protein in vitro involves enhanced recruitment of its substrate protein. The Journal of Biological Chemistry. 284: 12783-91. PMID 19299511 DOI: 10.1074/jbc.M809207200  0.48
2009 Davies BS, Yang SH, Farber E, Lee R, Buck SB, Andres DA, Spielmann HP, Agnew BJ, Tamanoi F, Fong LG, Young SG. Increasing the length of progerin's isoprenyl anchor does not worsen bone disease or survival in mice with Hutchinson-Gilford progeria syndrome. Journal of Lipid Research. 50: 126-34. PMID 18757838 DOI: 10.1194/jlr.M800424-JLR200  0.76
2008 Short JD, Houston KD, Dere R, Cai SL, Kim J, Johnson CL, Broaddus RR, Shen J, Miyamoto S, Tamanoi F, Kwiatkowski D, Mills GB, Walker CL. AMP-activated protein kinase signaling results in cytoplasmic sequestration of p27. Cancer Research. 68: 6496-506. PMID 18701472 DOI: 10.1158/0008-5472.CAN-07-5756  0.36
2008 Lu J, Choi E, Tamanoi F, Zink JI. Light-activated nanoimpeller-controlled drug release in cancer cells. Small (Weinheim An Der Bergstrasse, Germany). 4: 421-6. PMID 18383576 DOI: 10.1002/smll.200700903  0.76
2008 Ikeda K, Morigasaki S, Tatebe H, Tamanoi F, Shiozaki K. Fission yeast TOR complex 2 activates the AGC-family Gad8 kinase essential for stress resistance and cell cycle control. Cell Cycle (Georgetown, Tex.). 7: 358-64. PMID 18235227  0.76
2008 Watanabe M, Fiji HD, Guo L, Chan L, Kinderman SS, Slamon DJ, Kwon O, Tamanoi F. Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds. The Journal of Biological Chemistry. 283: 9571-9. PMID 18230616 DOI: 10.1074/jbc.M706229200  0.76
2008 Aspuria PJ, Tamanoi F. The Tsc/Rheb signaling pathway controls basic amino acid uptake via the Cat1 permease in fission yeast. Molecular Genetics and Genomics : Mgg. 279: 441-50. PMID 18219492 DOI: 10.1007/s00438-008-0320-y  0.48
2007 Lu J, Liong M, Sherman S, Xia T, Kovochich M, Nel AE, Zink JI, Tamanoi F. Mesoporous Silica Nanoparticles for Cancer Therapy: Energy-Dependent Cellular Uptake and Delivery of Paclitaxel to Cancer Cells. Nanobiotechnology : the Journal At the Intersection of Nanotechnology, Molecular Biology, and Biomedical Sciences. 3: 89-95. PMID 19936038 DOI: 10.1007/s12030-008-9003-3  0.76
2007 Aspuria PJ, Sato T, Tamanoi F. The TSC/Rheb/TOR signaling pathway in fission yeast and mammalian cells: temperature sensitive and constitutive active mutants of TOR. Cell Cycle (Georgetown, Tex.). 6: 1692-5. PMID 17637564  0.48
2007 Lu J, Liong M, Zink JI, Tamanoi F. Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small (Weinheim An Der Bergstrasse, Germany). 3: 1341-6. PMID 17566138 DOI: 10.1002/smll.200700005  0.76
2007 Castellano S, Fiji HD, Kinderman SS, Watanabe M, Leon Pd, Tamanoi F, Kwon O. Small-molecule inhibitors of protein geranylgeranyltransferase type I. Journal of the American Chemical Society. 129: 5843-5. PMID 17439124 DOI: 10.1021/ja070274n  0.76
2007 Yu F, Harada JN, Brown HJ, Deng H, Song MJ, Wu TT, Kato-Stankiewicz J, Nelson CG, Vieira J, Tamanoi F, Chanda SK, Sun R. Systematic identification of cellular signals reactivating Kaposi sarcoma-associated herpesvirus. Plos Pathogens. 3: e44. PMID 17397260 DOI: 10.1371/journal.ppat.0030044  0.76
2007 Urano J, Sato T, Matsuo T, Otsubo Y, Yamamoto M, Tamanoi F. Point mutations in TOR confer Rheb-independent growth in fission yeast and nutrient-independent mammalian TOR signaling in mammalian cells Proceedings of the National Academy of Sciences of the United States of America. 104: 3514-3519. PMID 17360675 DOI: 10.1073/pnas.0608510104  0.76
2007 Matsuo T, Otsubo Y, Urano J, Tamanoi F, Yamamoto M. Loss of the TOR kinase Tor2 mimics nitrogen starvation and activates the sexual development pathway in fission yeast Molecular and Cellular Biology. 27: 3154-3164. PMID 17261596 DOI: 10.1128/MCB.01039-06  0.76
2006 Patel PH, Tamanoi F. Increased Rheb-TOR signaling enhances sensitivity of the whole organism to oxidative stress. Journal of Cell Science. 119: 4285-92. PMID 17038544 DOI: 10.1242/jcs.03199  0.76
2006 Gelb MH, Brunsveld L, Hrycyna CA, Michaelis S, Tamanoi F, Van Voorhis WC, Waldmann H. Therapeutic intervention based on protein prenylation and associated modifications. Nature Chemical Biology. 2: 518-28. PMID 16983387 DOI: 10.1038/nchembio818  0.76
2006 Patel PH, Tamanoi F. Using Drosophila and yeast genetics to investigate a role for the Rheb GTPase in cell growth. Methods in Enzymology. 407: 443-54. PMID 16757344 DOI: 10.1016/S0076-6879(05)07036-9  0.76
2005 Urano J, Comiso MJ, Guo L, Aspuria PJ, Deniskin R, Tabancay AP, Kato-Stankiewicz J, Tamanoi F. Identification of novel single amino acid changes that result in hyperactivation of the unique GTPase, Rheb, in fission yeast. Molecular Microbiology. 58: 1074-86. PMID 16262791 DOI: 10.1111/j.1365-2958.2005.04877.x  0.76
2005 Gau CL, Kato-Stankiewicz J, Jiang C, Miyamoto S, Guo L, Tamanoi F. Farnesyltransferase inhibitors reverse altered growth and distribution of actin filaments in Tsc-deficient cells via inhibition of both rapamycin-sensitive and -insensitive pathways. Molecular Cancer Therapeutics. 4: 918-26. PMID 15956249 DOI: 10.1158/1535-7163.MCT-04-0347  0.48
2004 Kho Y, Kim SC, Jiang C, Barma D, Kwon SW, Cheng J, Jaunbergs J, Weinbaum C, Tamanoi F, Falck J, Zhao Y. A tagging-via-substrate technology for detection and proteomics of farnesylated proteins. Proceedings of the National Academy of Sciences of the United States of America. 101: 12479-84. PMID 15308774 DOI: 10.1073/pnas.0403413101  0.76
2004 Aspuria PJ, Tamanoi F. The Rheb family of GTP-binding proteins. Cellular Signalling. 16: 1105-12. PMID 15240005 DOI: 10.1016/j.cellsig.2004.03.019  0.48
2004 Uhlmann EJ, Li W, Scheidenhelm DK, Gau CL, Tamanoi F, Gutmann DH. Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation. Glia. 47: 180-8. PMID 15185396 DOI: 10.1002/glia.20036  0.36
2003 Patel PH, Thapar N, Guo L, Martinez M, Maris J, Gau CL, Lengyel JA, Tamanoi F. Drosophila Rheb GTPase is required for cell cycle progression and cell growth. Journal of Cell Science. 116: 3601-10. PMID 12893813 DOI: 10.1242/jcs.00661  0.76
2003 Tabancay AP, Gau CL, Machado IM, Uhlmann EJ, Gutmann DH, Guo L, Tamanoi F. Identification of dominant negative mutants of Rheb GTPase and their use to implicate the involvement of human Rheb in the activation of p70S6K. The Journal of Biological Chemistry. 278: 39921-30. PMID 12869548 DOI: 10.1074/jbc.M306553200  0.76
2002 Kato-Stankiewicz J, Hakimi I, Zhi G, Zhang J, Serebriiskii I, Guo L, Edamatsu H, Koide H, Menon S, Eckl R, Sakamuri S, Lu Y, Chen QZ, Agarwal S, Baumbach WR, ... ... Tamanoi F, et al. Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 99: 14398-403. PMID 12391290 DOI: 10.1073/pnas.222222699  0.48
2001 Tamanoi F, Kato-Stankiewicz J, Jiang C, Machado I, Thapar N. Farnesylated proteins and cell cycle progression. Journal of Cellular Biochemistry. Supplement. 64-70. PMID 11842430 DOI: 10.1002/jcb.10067  0.76
2001 Tamanoi F, Gau CL, Jiang C, Edamatsu H, Kato-Stankiewicz J. Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells. Cellular and Molecular Life Sciences : Cmls. 58: 1636-49. PMID 11706990  0.48
2001 Yang W, Tabancay AP, Urano J, Tamanoi F. Failure to farnesylate Rheb protein contributes to the enrichment of G0/G1 phase cells in the Schizosaccharomyces pombe farnesyltransferase mutant. Molecular Microbiology. 41: 1339-47. PMID 11580838 DOI: 10.1046/j.1365-2958.2001.02599.x  0.76
2000 Urano J, Tabancay AP, Yang W, Tamanoi F. The Saccharomyces cerevisiae Rheb G-protein is involved in regulating canavanine resistance and arginine uptake. The Journal of Biological Chemistry. 275: 11198-206. PMID 10753927 DOI: 10.1074/jbc.275.15.11198  0.76
2000 Yang W, Urano J, Tamanoi F. Protein farnesylation is critical for maintaining normal cell morphology and canavanine resistance in Schizosaccharomyces pombe. The Journal of Biological Chemistry. 275: 429-38. PMID 10617635  0.72
1998 Arellano M, Coll PM, Yang W, Duran A, Tamanoi F, Perez P. Characterization of the geranylgeranyl transferase type I from Schizosaccharomyces pombe. Molecular Microbiology. 29: 1357-67. PMID 9781874  0.72
1997 Yang W, Del Villar K, Urano J, Mitsuzawa H, Tamanoi F. Advances in the development of farnesyltransferase inhibitors: substrate recognition by protein farnesyltransferase. Journal of Cellular Biochemistry. Supplement. 27: 12-9. PMID 9591188  0.72
1997 Del Villar K, Mitsuzawa H, Yang W, Sattler I, Tamanoi F. Amino acid substitutions that convert the protein substrate specificity of farnesyltransferase to that of geranylgeranyltransferase type I. The Journal of Biological Chemistry. 272: 680-7. PMID 8995312  0.72
Show low-probability matches.